Matthew D. Breyer, MD (Distinguished Scientist CVM Janssen): Dr. Breyer received his MD from Harvard in 1979.  Following residency and nephrology training he served as Professor of Medicine in the division of Nephrology at Vanderbilt University Medical School from 1985-2007, where his work focused on causes of diabetic kidney disease and hypertension focusing on transgenic mouse models.  Dr. Breyer received numerous NIH and VA grant awards and from 2001-2006 headed the nephropathy sub-group of the NIH Animal Models of Diabetic Complications Consortium (AMDCC).  As a result of his interest in developing treatments for diabetic nephropathy he moved to Eli Lilly in 2007 to oversee a program to develop bio-therapeutics for diabetic kidney disease.  In 2009 he was appointed to the position of Chief Scientific Officer Lead Generation Biotechnology Discovery Research at Eli Lilly where he oversaw preclinical target identification and validation of biologics for chronic kidney, metabolic, neurologic, and oncologic diseases, and served until 2018.  In April 2018 Dr. Breyer joined the Janssen Cardiovascular and Metabolism group in Boston where he guides discovery and development of new drugs for kidney disease.